期刊文献+
共找到6篇文章
< 1 >
每页显示 20 50 100
抗-HEV ELISA试剂质控参比品的研制
1
作者 张华远 万宗举 +5 位作者 毛群颍 王佑春 高佳梅 刘东辉 王端 李河民 《中国生物制品学杂志》 CAS CSCD 1999年第1期46-47,共2页
采自献血员的血浆 ,经国外商品化试剂抗 - HEV EL ISA及国内外研究用抗 - HEV试剂检测 ,制备了我国第 1代抗 - HEV EL ISA试剂质控参比品 ,并获得卫生部认可。
关键词 制药 抗-HEV ELISA 试剂 质控参比品
下载PDF
甲型肝炎病毒抗原定量参比品的研制
2
作者 刘建生 庞伟 +5 位作者 孟明耀 马进 王萍 杨丽仙 陈统球 侯宗柳 《中国生物制品学杂志》 CAS CSCD 2005年第6期495-497,共3页
目的制备甲型肝炎病毒抗原定量参比品.方法依据<甲型肝炎灭活疫苗制造及检定规程>制备了1批甲肝病毒抗原参比品,并进行蛋白质含量测定、HAV蛋白纯度分析和酶标抗原含量标化.结果经纯化,杂蛋白去除率达99.9%,参比品的纯度大于95%;... 目的制备甲型肝炎病毒抗原定量参比品.方法依据<甲型肝炎灭活疫苗制造及检定规程>制备了1批甲肝病毒抗原参比品,并进行蛋白质含量测定、HAV蛋白纯度分析和酶标抗原含量标化.结果经纯化,杂蛋白去除率达99.9%,参比品的纯度大于95%;抗原含量在20~80EU/ml范围内,抗原含量的对数与其A值呈剂量-效应关系.结论该参比品可用于甲肝病毒ELISA定性及定量标定. 展开更多
关键词 甲型肝炎病毒 抗原定量 参比品 蛋白质 定量标定
下载PDF
我国高质量丙肝诊断试剂及第三代国家标准参比品研究 被引量:2
3
作者 祁自柏 《医学研究通讯》 2002年第11期5-8,共4页
丙型肝炎病毒是新近发现的与输血有关的非甲非乙型肝炎病毒,患者易发展成慢性肝炎,肝硬化及肝癌.根据"八·五"期间对全国30个省市自治区正常人群中丙肝病毒(HCV)携带者情况的调查,抗HCV流行率在1.35%~5.89%之间,平均为3.... 丙型肝炎病毒是新近发现的与输血有关的非甲非乙型肝炎病毒,患者易发展成慢性肝炎,肝硬化及肝癌.根据"八·五"期间对全国30个省市自治区正常人群中丙肝病毒(HCV)携带者情况的调查,抗HCV流行率在1.35%~5.89%之间,平均为3.2%.在高危人群中携带率更高,有报道称在有些地方的献血员中其丙肝感染率大于50%,丙型肝炎病毒现已成为输血后肝炎的主要病因,阻断丙肝病毒的传播,保护人民健康已成为刻不容缓的任务. 展开更多
关键词 诊断试剂 国家标准 参比品 丙型肝炎 丙肝病毒抗体
下载PDF
甲型肝炎
4
《传染病网络动态》 2006年第6期98-99,共2页
甲型肝炎病毒抗原定量参比品的研制;急性甲型肝炎与急性戊型肝炎临床对比分析。
关键词 甲型肝炎病毒抗原 临床对比分析 急性戊型肝炎 急性甲型肝炎 参比品
下载PDF
Brief introduction for application of the USA national drug code 被引量:2
5
作者 Dongsheng Yang Lingyun Ma +1 位作者 Jianzhao Niu Mingdi Xu 《Journal of Chinese Pharmaceutical Sciences》 CAS CSCD 2019年第3期203-208,共6页
The reference listed drug (RLD) adopted in the USA orange book is the important source of the Chinese comparator product directories of generic medicinal products. Therefore, its availability has the vital significane... The reference listed drug (RLD) adopted in the USA orange book is the important source of the Chinese comparator product directories of generic medicinal products. Therefore, its availability has the vital significanee for pharmaceutical enterprise to carry out the re-evaluation of gen eric medici nal products and study of generic medicinal products. The nati onal drug code (NDC) is the unique, 3-segment number for each drug product in USA, and it serves as a universal product identifier for drugs. While the NDC directory adopts the infbrmation of drug products in the current commercial distribution, including all of the prescription drug and over the counter (OTC) drug products. The composition and configuration of the NDC number are systemically elaborated in this paper, as well as the data source, development history and supporting measures of the NDC directory. At the same time, by taking drugs, which are adopted in the Chinese comparator product directory of generic medicinal product (first batch) and sourced from USA orange book, as example, it introduces the application of the NDC directory in the availability aspect of the Chinese comparator products to facilitate the Chinese or foreign pharmaceutical manufacturers to search, identify and purchase the suitable RLD sourced from USA orange book. Moreover, it can provide referenee for Chinese drug regulatory to prepare the Chinese comparator product directories of generic medicinal products. 展开更多
关键词 National drug code Comparator product Re-evaluation of generic medicinal product Orange book
原文传递
Brief introduction for application of USA authorized generic drugs 被引量:1
6
作者 Dongsheng Yang Lingyun Ma +1 位作者 Jianzhao Niu Mingdi Xu 《Journal of Chinese Pharmaceutical Sciences》 CAS CSCD 2019年第6期439-445,共7页
The authorized generic drugs(AGs)are drug products marketed in the USA with the permission of sponsor or holder of the approved brand name drug(usually refers to an innovator drug).Other than the fact that it does not... The authorized generic drugs(AGs)are drug products marketed in the USA with the permission of sponsor or holder of the approved brand name drug(usually refers to an innovator drug).Other than the fact that it does not have the brand name on its label,it is the exact same drug product as the brand name product.In China,for those published comparator products of generic drug products,the market availability is the first question to affect the smooth development and investigation for the process of the re-evaluation of the generic drugs.In the present paper,we systemically elaborated the definition,classification and relevant background of the AGs,as well as their differences to the generic drugs.At the same time,by taking drug products,which are adopted in the Chinese comparator product directories for generic medicinal products(first batch)and sourced from USA orange book,as examples,we introduced the searching process of the AGs with the integration of FDA listing of AGs,the USA orange book and the USA national drug code directory.It can facilitate the domestic and foreign pharmaceutical enterprises to search,identify and purchase the corresponding AGs of the designated comparator product when question emerges to its market availability. 展开更多
关键词 Authorized generic drugs New drug application National drug code Comparator product Re-evaluation of generic medicinal product Orange book
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部